AstraZeneca is making a sweeping push to sharpen its lead in oncology, unveiling a deep pipeline of new clinical data at the American Society of Clinical Oncology Annual Meeting taking place 29 May–2 June 2026.
The company says the breadth of results reinforces its long-term ambition to “eliminate cancer as a cause of death” while also advancing treatments for rare diseases.
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies, including 25 oral presentations spanning oncology and rare disease programs.
At the centre of attention are multiple late-stage and early clinical readouts that signal both expansion and diversification of its cancer portfolio:
One of the headline studies, EMERALD-3, evaluates the combination of Imfinzi (durvalumab) and Imjudo (tremelimumab), with or without lenvatinib and transarterial chemoembolisation (TACE), in patients with unresectable hepatocellular carcinoma eligible for embolisation.
In rare disease, the CARES Phase III programme examines anselamimab from Alexion, targeting light chain (AL) amyloidosis, including subgroup analyses based on kappa and lambda free light chains, highlighting its potential as a first-in-class anti-fibril therapy.
Breast cancer remains a major focus. The SERENA-6 trial reports final progression-free survival 2 data for camizestrant in combination with CDK4/6 inhibitors in HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations, alongside ctDNA clearance findings tied to longer-term outcomes.
In gynecologic cancers, the BLUESTAR study updates safety and efficacy for the investigational ADC puxitatug samrotecan in relapsed or metastatic B7-H4-positive endometrial and ovarian cancers, following its recent FDA Breakthrough Therapy Designation.
Early-stage innovation also features prominently, including first-in-human results for AZD3470 in Hodgkin lymphoma, initial data for NT-175 T-cell receptor therapy in TP53-mutated solid tumours, and multiple antibody-drug conjugate and targeted therapy programs across solid tumours.
Further highlights include TROPION-Breast02 evaluating Datroway (datopotamab deruxtecan) in triple-negative breast cancer, DESTINY-Breast09 exploring treatment outcomes for Enhertu (fam-trastuzumab deruxtecan-nxki), and the POTOMAC study reporting five-year survival data for Imfinzi in non-muscle-invasive bladder cancer.
Leadership at AstraZeneca framed the ASCO data as a turning point for next-generation cancer therapy.
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “The data at ASCO for our innovative medicines and next-wave assets further our strategy to redefine patient outcomes by taking novel combinations into earlier stages of disease and advancing new modalities.
"New data for Enhertu, Datroway and camizestrant reinforce their transformational potential in breast cancer. We’re also excited to share first clinical data for our T-cell receptor therapy, NT-175, and our PRMT5 inhibitor, AZD3470, as well as updated data for our most advanced in-house antibody drug conjugate, Puxi-Sam, which was recently granted Breakthrough Therapy Designation by the FDA. Collectively, these datasets underscore the strength and depth of our oncology pipeline.”
Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca, said: “The EMERALD-3 data for Imfinzi and Imjudo in early liver cancer exemplify our successful strategy to move immunotherapy regimens into earlier stages of cancer where we can further improve outcomes for patients.
"With more than a dozen different indications approved across five cancer medicines in the last six months alone, we are reaching more patients with our growing portfolio, underscoring both the quality of our innovation and the strength of our business.”
Gianluca Pirozzi, Head of Development, Regulatory and Safety, Alexion, said: "Results from the CARES Phase III clinical programme highlight the pioneering potential of anselamimab as a first-in-class, anti-fibril therapy for patients with kappa light chain amyloidosis. Its novel mechanism of action is designed to target and deplete amyloid deposits in affected organs, with potential to extend survival and reduce cardiovascular hospitalisations."
The announcements underscore AstraZeneca’s dual-track strategy: push proven oncology assets into earlier lines of therapy while accelerating experimental modalities from ADCs to T-cell therapies and targeted small molecules.
